Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

July 26, 2019

Primary Completion Date

August 31, 2022

Study Completion Date

December 14, 2026

Conditions
Sickle Cell Disease (SCD)
Interventions
DRUG

Crizanlizumab (SEG101)

"Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV."

DRUG

Placebo

Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.

Trial Locations (59)

123

Novartis Investigative Site, Khoudh

1000

Novartis Investigative Site, Brussels

1070

Novartis Investigative Site, Brussels

1434

Novartis Investigative Site, Tripoli

2013

Novartis Investigative Site, Soweto

2650

Novartis Investigative Site, Edegem

13353

Novartis Investigative Site, Berlin

13885

Novartis Investigative Site, Marseille

16128

Novartis Investigative Site, Genova

20122

Novartis Investigative Site, Milan

22110

Novartis Investigative Site, Irbid

28034

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

28204

Levine Cancer Insitute Carolinas Healthcare System, Charlotte

30342

Childrens Healthcare of Atlanta, Atlanta

37134

Novartis Investigative Site, Verona

38163

Univ of Tenn Health Sciences Ctr, Memphis

45147

Novartis Investigative Site, Essen

50937

Novartis Investigative Site, Cologne

70376

Novartis Investigative Site, Stuttgart

75015

Novartis Investigative Site, Paris

77030

University of Texas Health Science Center at Houston, Houston

80138

Novartis Investigative Site, Napoli

94010

Novartis Investigative Site, Créteil

230004

Novartis Investigative Site, Montería

500082

Novartis Investigative Site, Hyderabad

751003

Novartis Investigative Site, Bhubaneswar

5602310

Novartis Investigative Site, Valledupar

02118

Boston Medical Center, Boston

41253-190

Novartis Investigative Site, Salvador

66033 000

Novartis Investigative Site, Belém

50070-170

Novartis Investigative Site, Recife

20211-030

Novartis Investigative Site, Rio de Janeiro

90035-003

Novartis Investigative Site, Porto Alegre

14048-900

Novartis Investigative Site, Ribeirão Preto

01232-010

Novartis Investigative Site, São Paulo

05403 000

Novartis Investigative Site, São Paulo

08270-070

Novartis Investigative Site, São Paulo

M5G 2C4

Novartis Investigative Site, Toronto

H2X 1R9

Novartis Investigative Site, Montreal

080020

Novartis Investigative Site, Barranquilla

FIN 00290

Novartis Investigative Site, Helsinki

0437-0594

Novartis Investigative Site, Accra

115 27

Novartis Investigative Site, Athens

265 04

Novartis Investigative Site, Pátrai

GR 54636

Novartis Investigative Site, Thessaloniki

113-0236

Novartis Investigative Site, Beirut

1105 AZ

Novartis Investigative Site, Amsterdam

3015 GD

Novartis Investigative Site, Rotterdam

2545 AA

Novartis Investigative Site, The Hague

0801

Novartis Investigative Site, Panama City

Novartis Investigative Site, Panama City

08035

Novartis Investigative Site, Barcelona

01330

Novartis Investigative Site, Adana

S10 2JF

Novartis Investigative Site, Sheffield

CB2 0QQ

Novartis Investigative Site, Cambridge

SE1 9RT

Novartis Investigative Site, London

SE5 9RS

Novartis Investigative Site, London

S10 2TH

Novartis Investigative Site, Sheffield

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY